Business
InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa
InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formula...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Dec. 9, 2019\n\n\n\nVANCOUVER, Dec. 9, 2019 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX: IN; OTCQX: IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced it has received regulatory and ethics board approval of its Clinical Trial Application (\"CTA\") to conduct a Phase 1 trial in the Netherlands for INM-755, a cannabinoid-based topical cream.  The Company intends to initiate subject recruitment immediately.  \n\n \n \n\n \nThe initial clinical trial, Study 755-101-HV, is a randomized, double-blind, vehicle-controlled, Phase 1 study designed to evaluate the local and systemic safety, tolerability, and pharmacokinetics of INM-755 applied daily on intact skin in healthy volunteers. Two strengths of INM-755 cream, plus vehicle-only, will be evaluated in 22 adult subjects over a 14-day treatment period.  \nINM-755, the Company's lead product candidate, is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (\"EB\"), a rare genetic skin disease characterized by fragile skin that can lead to extensive blistering and wounding. It may also address the underlying disease by enhancing skin integrity in a subset of EB patients. \n\"INM-755 is the first rare cannabinoid formulation for the treatment and symptomatic relief of EB to advance to clinical trials,\" commented Eric A. Adams, President and CEO of InMed Pharmaceuticals. \"Initiating this Phase 1 trial of INM-755 was one of our key corporate objectives for 2019. It represents a significant step in bringing forward a potential new treatment option for EB patients who are in significant need of new and more effective treatment options. The extensive preclinical safe...